High level expression of recombinant human erythropoietin having a modified 5′-UTR
US7893240B2 · kind B2 · utility
0Cited by
26References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 25, 2008 |
| Grant date | Feb 22, 2011 |
| Priority date | — |
| Expiry date | Jul 25, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an expression construct capable of producing high levels of erythropoietin in mammalian cells. More particularly, the expression construct includes an erythropoietin coding region fused to a unique 5′-UTR sequence and a truncated 3′-UTR. The present invention also provides methods of synthesizing large amounts of erythropoietin and in increasing serum erythropoietin level in individuals in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.